Roche launches Vabysmo® (faricimab), the first and only bispecific monoclonal antibody for the eye, to treat two leading causes of vision loss.
by Prashant Kapadia/NHN Vabysmo targets and inhibits two disease pathways that cause neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema …








